Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Stayble Therapeutics AB is a pharmaceutical company specializing in the development of novel treatments for chronic back pain. The company's primary focus lies in addressing degenerative disc disease, a prevalent condition causing pain in the lumbar region. Utilizing an innovative approach, Stayble is working on a pioneering injectable drug aimed at mitigating the root causes of spinal degeneration and offering long-term relief for patients. The Swedish-based enterprise is engaged in advancing its treatment through various clinical trial phases to ensure safety and efficacy. Stayble Therapeutics plays a critical role in the healthcare industry, specifically targeting unmet medical needs in the orthopedic and pain management sectors. The company’s efforts hold significant implications for improving patient quality of life and potentially reducing the reliance on invasive surgical procedures. Through its groundbreaking research and development, Stayble Therapeutics is positioned as a key player in the biopharmaceutical market, contributing to advancements in non-surgical solutions for chronic pain management.
kr 0.02
+kr 0.00 (+0.00%)
Price from 14 days ago
Negative free cash flow of -kr 7M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 11M
▲ +44.2% YoY
Op. Margin
—
ROIC
-74.72%
▲ +8.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 6M
▲ +54.2% YoY
Op. Cash Flow (TTM)
-kr 6M
▲ +54.2% YoY
Net Debt
-kr 2M
Net Cash Position
Cash & Equiv.
kr 2M
Continue Research
Stayble Therapeutics AB (STABL.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Stayble Therapeutics AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Stayble Therapeutics AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -74.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh STABL.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.